Dose intensity and high dose therapy. Two different concepts

“Dose response” refers to a direct relationship between the amount of chemotherapy administered and observed degree of antitumor effect. What is often implied by the term is the administration of pulsed, high dose therapy, resulting in very high peak concentrations. Clinically, this has been translated as multiple alkylating agent‐based regimens requiring intensive supportive care and associated with substantial morbidity and an appreciable mortality risk. Such regimens typically are given as consolidation after an initial period of standard outpatient therapy and may require autologous hematopoietic stem cell support.

[1]  R. Livingston,et al.  Feasibility of dose–intensive continuous 5–fluorouracil, doxorubicin, and cyclophosphamide as adjuvant therapy for breast cancer , 1993, Cancer.

[2]  B. Teicher,et al.  A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Spurr,et al.  Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. , 1991, The New England journal of medicine.

[4]  M. Nooij,et al.  "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). , 1991, European journal of cancer.

[5]  M. Raffeld,et al.  bcl-1, t(11;14), and mantle cell-derived lymphomas. , 1991, Blood.

[6]  W. Hryniuk,et al.  The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Hortobagyi,et al.  Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Gent,et al.  A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Wolberg,et al.  Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Livingston,et al.  Combination chemotherapy and high‐dose cyclophosphamide intensification for poor prognosis breast cancer. A southwest oncology group study , 1989, Cancer.

[11]  R. Strieter,et al.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofylline , 1988 .

[12]  I. Tannock,et al.  A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Tattersall,et al.  Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.

[14]  R. Livingston,et al.  Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer , 1987, Cancer.

[15]  G. Hortobagyi,et al.  Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Janossy Bone marrow purging. , 1987, Immunology today.

[17]  M. Levine,et al.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Bonadonna,et al.  Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Hortobagyi,et al.  Complete remissions in metastatic breast cancer treated with combination drug therapy. , 1979, Annals of internal medicine.

[21]  J. O'fallon,et al.  Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. , 1979, JAMA.